Form 4: MaxCyte CEO Granted Stock Options
SEC Form 4 Filing
MaxCyte's CEO, Maher Masoud, was granted stock options for 347,500 shares on March 14, 2025.
Summary
- Maher Masoud, the President and CEO of MaxCyte, Inc., was granted employee stock options on March 14, 2025.
- The options grant covers 347,500 shares of MaxCyte common stock.
- The exercise price of the options is $3.29 per share.
- The options vest over time, with 25% vesting on March 14, 2026, and the remaining 75% vesting in 36 equal monthly installments thereafter, contingent upon continued service.
- The options expire on March 13, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. There are no explicitly negative aspects presented in the document.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize stock options to incentivize their leadership teams.
- The size of the grant and vesting schedule are generally benchmarked against peer companies of similar size and stage of development.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase shareholder value.
- Employees may see the grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 03/14/2025 | Date of the stock option grant. |
| 03/14/2026 | Date when 25% of the options begin to vest. |
| 03/13/2035 | Expiration date of the stock options. |
| 03/18/2025 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.